Reforming Drug Price Regulation: Using Tools That Work
INQUIRY: The Journal of Health Care Organization, Provision, and Financing · 2025
DOI: 10.1177/00469580251335844 ↗Kurz gefasst
Fachartikel in der Zeitschrift INQUIRY: The Journal of Health Care Organization, Provision, and Financing, 2025. Verfasst von Deborah Williams und 2 weiteren Autor:innen. Beteiligte Einrichtung: Health Policy Insights LLC, Greer, SC, USA. Hauptthemen laut MEDLINE: Drug Costs, Government Regulation, Health Care Reform. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Drug pricing reform to increase affordability has historically relied on increases in regulation often with a focus on administrative pricing for public programs in order to try to lower drug costs. This paper examines the consequences of this strategy, pointing out that regulated prices fail to drive affordability, create unintended, hidden costs to the system, and drive demand for a body of ever-growing regulatory interventions to address shortfalls created by prior policies. Within this context, the paper examines examples of regulations affecting large percentages of government payments the Medicaid Drug Rebate, the Inflation Reduction Act Maximum Fair Price, and the Average Sales Price formula in Medicare B enumerating how each of these programs that direct funds to Medicare or Medicaid only create hidden systematic costs when considered from the total market perspective. Next, a new paradigm for drug pricing reform philosophy is suggested, with a focus on market-based interventions to reform existing government regulation aimed at improving competition and consider examples of effective private market policies including co-insurance/copayment reform, private formularies, specialty pharmacies, and value-based contracting. The paper concludes by arguing that shifting from a programmatic view of affordability to an understanding of the regulatory effect on costs in the drug market, including regulatory burden reduction, is the best way to drive affordability for payers and thus ultimately for employers and consumers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Health Policy Insights LLC, Greer, SC, USA.
- The Cigna Group, Nashville, TN, USA.
- Johns Hopkins University School of Medicine, Baltimore, MD, USA.
- American Enterprise Institute, Washington, DC, USA.
ORCID-Profile: Deborah Williams, Brian J Miller
Zitieren
APA
Williams, D., Zima, S. C., & Miller, B. J. (2025). Reforming Drug Price Regulation: Using Tools That Work. INQUIRY: The Journal of Health Care Organization, Provision, and Financing. https://doi.org/10.1177/00469580251335844
Vancouver
Williams D, Zima SC, Miller BJ. Reforming Drug Price Regulation: Using Tools That Work. INQUIRY: The Journal of Health Care Organization, Provision, and Financing. 2025. doi:10.1177/00469580251335844
BibTeX
@article{Williams2025,
author = {Williams, Deborah and Zima, Steven C and Miller, Brian J},
title = {Reforming Drug Price Regulation: Using Tools That Work},
journal = {INQUIRY: The Journal of Health Care Organization, Provision, and Financing},
year = {2025},
doi = {10.1177/00469580251335844}
}
EUVIMED